CN110522906A - 多维、多价、前列腺癌特异性肿瘤抗原组装体的制备方法 - Google Patents
多维、多价、前列腺癌特异性肿瘤抗原组装体的制备方法 Download PDFInfo
- Publication number
- CN110522906A CN110522906A CN201910699812.2A CN201910699812A CN110522906A CN 110522906 A CN110522906 A CN 110522906A CN 201910699812 A CN201910699812 A CN 201910699812A CN 110522906 A CN110522906 A CN 110522906A
- Authority
- CN
- China
- Prior art keywords
- preparation
- antigen
- multivalence
- prostatic cancer
- cancer specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 58
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 56
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 50
- 239000000427 antigen Substances 0.000 title claims abstract description 35
- 108091007433 antigens Proteins 0.000 title claims abstract description 31
- 102000036639 antigens Human genes 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 37
- 229920001184 polypeptide Polymers 0.000 claims abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 21
- 239000012634 fragment Substances 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 14
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims abstract description 9
- 238000000746 purification Methods 0.000 claims abstract description 9
- 230000002068 genetic effect Effects 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 238000012827 research and development Methods 0.000 claims abstract description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 229920001661 Chitosan Polymers 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 238000000855 fermentation Methods 0.000 claims description 7
- 230000004151 fermentation Effects 0.000 claims description 7
- 229910021389 graphene Inorganic materials 0.000 claims description 7
- 229920002521 macromolecule Polymers 0.000 claims description 7
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims description 6
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 5
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 5
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 5
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 5
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 5
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 5
- 229920002643 polyglutamic acid Polymers 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 239000000439 tumor marker Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 241000235058 Komagataella pastoris Species 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 238000013467 fragmentation Methods 0.000 claims description 3
- 238000006062 fragmentation reaction Methods 0.000 claims description 3
- 229940030749 prostate cancer vaccine Drugs 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 229920001503 Glucan Polymers 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 6
- 210000000987 immune system Anatomy 0.000 abstract description 3
- 230000028993 immune response Effects 0.000 abstract description 2
- 125000000524 functional group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 8
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000001376 precipitating effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 240000005708 Eugenia stipitata Species 0.000 description 3
- 235000006149 Eugenia stipitata Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 241001474374 Blennius Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100040553 FXYD domain-containing ion transport regulator 3 Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000893731 Homo sapiens FXYD domain-containing ion transport regulator 3 Proteins 0.000 description 1
- 101001001272 Homo sapiens Prostatic acid phosphatase Proteins 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000009167 androgen deprivation therapy Methods 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037966 cold tumor Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- JFINOWIINSTUNY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1CCNC1 JFINOWIINSTUNY-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910699812.2A CN110522906B (zh) | 2019-07-31 | 2019-07-31 | 多维、多价、前列腺癌特异性肿瘤抗原组装体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910699812.2A CN110522906B (zh) | 2019-07-31 | 2019-07-31 | 多维、多价、前列腺癌特异性肿瘤抗原组装体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110522906A true CN110522906A (zh) | 2019-12-03 |
CN110522906B CN110522906B (zh) | 2023-04-07 |
Family
ID=68660505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910699812.2A Active CN110522906B (zh) | 2019-07-31 | 2019-07-31 | 多维、多价、前列腺癌特异性肿瘤抗原组装体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110522906B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1362263A (zh) * | 2001-01-04 | 2002-08-07 | 北京迪威华宇生物技术有限公司 | 预防和治疗人前列腺癌的重组蛋白疫苗 |
CN1872028A (zh) * | 2006-04-28 | 2006-12-06 | 深圳市人民医院 | 一种免疫磁性纳米微球及其制备方法和用途 |
CN101258166A (zh) * | 2004-04-22 | 2008-09-03 | 阿根西斯公司 | 与steap-1蛋白结合的抗体及其衍生的分子 |
CN105343874A (zh) * | 2015-11-11 | 2016-02-24 | 固安鼎泰海规生物科技有限公司 | 一种前列腺癌核酸疫苗 |
CN106729777A (zh) * | 2017-02-28 | 2017-05-31 | 华南理工大学 | 一种靶向前列腺癌细胞的纳米壳聚糖超声微泡及其制备与应用 |
-
2019
- 2019-07-31 CN CN201910699812.2A patent/CN110522906B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1362263A (zh) * | 2001-01-04 | 2002-08-07 | 北京迪威华宇生物技术有限公司 | 预防和治疗人前列腺癌的重组蛋白疫苗 |
CN101258166A (zh) * | 2004-04-22 | 2008-09-03 | 阿根西斯公司 | 与steap-1蛋白结合的抗体及其衍生的分子 |
CN1872028A (zh) * | 2006-04-28 | 2006-12-06 | 深圳市人民医院 | 一种免疫磁性纳米微球及其制备方法和用途 |
CN105343874A (zh) * | 2015-11-11 | 2016-02-24 | 固安鼎泰海规生物科技有限公司 | 一种前列腺癌核酸疫苗 |
CN106729777A (zh) * | 2017-02-28 | 2017-05-31 | 华南理工大学 | 一种靶向前列腺癌细胞的纳米壳聚糖超声微泡及其制备与应用 |
Non-Patent Citations (3)
Title |
---|
徐勇主编: "《前列腺癌》", 31 July 2009, 科学技术文献出版社 * |
梅兴国主编: "《微载体药物递送系统》", 30 November 2009, 华中科技大学出版社 * |
郭连英: "Hca-F抗原-HSP70BCG疫苗免疫对小鼠肝癌Hca-F的免疫保护效应", 《中国老年学杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN110522906B (zh) | 2023-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS58157723A (ja) | インタ−ロイキン2を含有してなる免疫療法剤 | |
JPH11502413A (ja) | 分泌腺発現による遺伝子治療 | |
CN106906230B (zh) | 重组药物载体蛋白基因及其制备方法与应用 | |
WO2009048166A1 (ja) | 細胞移植療法に用いられる心疾患治療薬 | |
CN113121704B (zh) | 基于纳米颗粒的冠状病毒疫苗 | |
CN110215522A (zh) | 一种CRISPR/Cas9递送系统及其制备方法和应用 | |
CN108588026A (zh) | 高表达il10的临床级间充质干细胞的制备方法及其用途 | |
US20030219419A1 (en) | Alteration of cell membrane for new functions | |
CN109893647A (zh) | 重组的弹性蛋白酶蛋白质及其制备方法和用途 | |
CN109865134A (zh) | 一种杂交纳米肿瘤疫苗的制备方法及其应用 | |
Zhang et al. | A programmable oral bacterial hydrogel for controllable production and release of nanovaccine for tumor immunotherapy | |
CN105218682A (zh) | 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途 | |
CN101850124A (zh) | 白蛋白纳米-超声微泡载组织型纤溶酶原激活物基因靶向体系及其制备方法 | |
JPH04501853A (ja) | 大型多価免疫原 | |
CN110522906A (zh) | 多维、多价、前列腺癌特异性肿瘤抗原组装体的制备方法 | |
Nie et al. | A single-shot prophylactic tumor vaccine enabled by an injectable biomembrane hydrogel | |
CN102228698A (zh) | Hpv58型治疗性复合基因疫苗及其构建方法 | |
AU764205B2 (en) | Use of an enterobacterium protein OmpA for specific targeting towards antigen-presenting cells | |
CN104292341A (zh) | 一种凝血八因子融合蛋白及其制备方法和用途 | |
CN108218978A (zh) | 一种重组白细胞介素18及其制备方法与应用 | |
RU2377249C2 (ru) | Биологически активные производные пептида vapeehptllteaplnpk | |
CN107899017B (zh) | 一种天然生物纳米靶向药物复合体材料及其制备方法和应用 | |
CN114099664A (zh) | 一种基于Treg细胞外泌体的靶向协同药物体系及其制备方法 | |
JPH08508641A (ja) | ウイルスタンパク質による免疫応答刺激 | |
CN102260352B (zh) | 靶向性白细胞介素融合蛋白及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Niu Yuanjie Inventor after: Chen Jiatong Inventor after: Yu Qilin Inventor after: Yang Yang Inventor after: Guo Linpei Inventor after: Cai Qiliang Inventor after: Shang Zhiqun Inventor after: Tang Huiqin Inventor before: Niu Yuanjie Inventor before: Chen Jiatong Inventor before: Lin Pingsheng Inventor before: Yu Qilin Inventor before: Yang Yang Inventor before: Guo Linpei Inventor before: Cai Qiliang Inventor before: Shang Zhiqun Inventor before: Tang Huiqin |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220915 Address after: 300000 No. 23, Pingjiang Road, Hexi District, Tianjin Applicant after: TIANJIN INSTITUTE OF UROLOGY Applicant after: Panru Biotechnology (Tianjin) Co.,Ltd. Address before: No.23 Pingjiang Road, Hexi District, Tianjin 300202 Applicant before: TIANJIN INSTITUTE OF UROLOGY Applicant before: TIANJIN XINPINGTAI BIOTECHNOLOGY CO.,LTD. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240527 Address after: Building 1-301-A324, Building 8, Huiying Industrial Park, No. 86 Zhonghuan West Road, Tianjin Binhai New Area Pilot Free Trade Zone (Airport Economic Zone), 300000 RMB Patentee after: Panru Biotechnology (Tianjin) Co.,Ltd. Country or region after: China Address before: 300000 No. 23, Pingjiang Road, Hexi District, Tianjin Patentee before: TIANJIN INSTITUTE OF UROLOGY Country or region before: China Patentee before: Panru Biotechnology (Tianjin) Co.,Ltd. |